Extending Treatment Intervals with Durable Therapies for nAMD and DME

home / peers-and-perspective / extending-treatment-intervals-with-durable-therapies-for-namd-and-dme

Retina specialists discuss therapies that promise to reduce the treatment burden of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) through extended durability. They also highlight the latest clinical data on the efficacy and safety of these therapies.

© 2024 MJH Life Sciences

All rights reserved.